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Abstract 
Targeted photodynamic therapy (PDT) has the potential to selectively damage tumor tissue and to 
increase tumor vessel permeability. Here we characterize the tissue biodistribution of two 
EGFR-targeted nanobody-photosensitizer conjugates (NB-PS), the monovalent 7D12-PS and the 
biparatopic 7D12-9G8-PS. In addition, we report on the local and acute phototoxic effects triggered by 
illumination of these NB-PS which have previously shown to lead to extensive tumor damage. 
Methods: Intravital microscopy and the skin-fold chamber model, containing OSC-19-luc2-cGFP 
tumors, were used to investigate: a) the fluorescence kinetics and distribution, b) the vascular response 
and c) the induction of necrosis after illumination at 1 or 24 h post administration of 7D12-PS and 
7D12-9G8-PS. In addition, dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) of a solid 
tumor model was used to investigate the microvascular status 2 h after 7D12-PS mediated PDT. 
Results: Image analysis showed significant tumor colocalization for both NB-PS which was higher for 
7D12-9G8-PS. Intravital imaging showed clear tumor cell membrane localization 1 and 2 h after 
administration of 7D12-9G8-PS, and fluorescence in or close to endothelial cells in normal tissue for both 
NB-PS. PDT lead to vasoconstriction and leakage of tumor and normal tissue vessels in the skin-fold 
chamber model. DCE-MRI confirmed the reduction of tumor perfusion after 7D12-PS mediated PDT. 
PDT induced extensive tumor necrosis and moderate normal tissue damage, which was similar for both 
NB-PS conjugates. This was significantly reduced when illumination was performed at 24 h compared to 
1 h after administration. 
Discussion: Although differences were observed in distribution of the two NB-PS conjugates, both led 
to similar necrosis. Clearly, the response to PDT using NB-PS conjugates is the result of a complex 
mixture of tumor cell responses and vascular effects, which is likely to be necessary for a maximally 
effective treatment. 
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Introduction 
Targeted strategies to deliver a photosensitizer 
to tumor cells have the potential to improve the 
therapeutic effect of photodynamic therapy (PDT) 
[1-5]. PDT involves the administration of a 
photosensitizer and the application of light with the 
appropriate wavelength [1,2]. After absorption of 
light by the photosensitizer, a range of photochemical 
reactions occur that, in the presence of oxygen, leads 
to the formation of predominantly singlet oxygen 
[1,2]. The highly reactive singlet oxygen causes 
damage to nearby proteins and lipids resulting in 
cellular, vascular and immunological responses that 
ultimately encompass the PDT response [1]. In 
general, clinically used photosensitizers are 
hydrophobic, which promotes cell binding but 
provides no tumor specificity. As a result, a 2 to 4 
days interval between photosensitizer administration 
and light delivery is common to obtain an optimum 
tumor to normal tissue ratio. In addition, patients 
become light sensitive, for several weeks, due to 
skin-photosensitization. Increased tumor specific 
uptake of the photosensitizer has the potential to lead 
to significantly better tumor responses, much less 
normal tissue damage and a decreased skin 
photosensitization [1-3]. Increased expression levels 
of specific receptors on tumor cells can be used to 
target these cells. In head and neck cancer, 83% of 
tumors show overexpression of the epidermal growth 
factor receptor (EGFR), which is commonly used as a 
target for various targeted therapies [6]. For targeted 
PDT a range of approaches have been explored, such 
as the direct conjugation of photosensitizer to 
antibodies or peptides, or targeted drug delivery 
systems where multiple photosensitizer are loaded 
into a liposome or other nanoparticles [4,5,7-14]. 
We have been developing an alternative 
approach using nanobodies [15-18]. Nanobodies are 
the smallest naturally derived antigen-binding 
fragments that consist of the variable domain of a 
heavy-chain antibody [19]. The characteristics of 
nanobodies make them favorable for targeted drug 
delivery as they bind specifically and with high 
affinity to their antigens, are relatively small, stable, 
water soluble and have low immunogenic potential 
[19-22]. The monovalent 7D12 and the biparatopic 
7D12-9G8 nanobodies specifically target EGFR and 
compete with EGF for binding to EGFR [23]. In 
contrast to the monovalent 7D12 nanobody, the 
biparatopic 7D12-9G8 leads to a more rapid EGFR 
internalization by inducing receptor clustering 
[15,24]. After conjugation to the water soluble 
photosensitizer IRDye700DX, a silicon- 
phthalocyanine derivative that absorbs and emits NIR 
light, these nanobodies act as a carrier of 
photosensitizer and can be used for targeted PDT or 
tumor targeted fluorescence guided imaging [4,25,26]. 
Recently we have shown promising results in 
vitro and in vivo using nanobody-photosensitizer 
(NB-PS), as an alternative approach for targeted PDT 
[15,16]. In vitro we have shown a clear relationship 
between level of EGFR expression, fluorescence 
intensity and PDT efficacy for both 7D12-PS and 
7D12-9G8-PS [15]. Subsequently, in an in vivo study 
employing an orthotopic tongue model transplanted 
with an oral squamous cell carcinoma expressing 
green fluorescent protein (OSC-19-luc2-cGFP), we 
used quantitative fluorescence spectroscopy to 
determine the NB-PS distribution in time after 
administration [16]. The fluorescence intensity in 
tumor and normal skin tissue was significantly higher 
for 7D12-9G8-PS compared to 7D12-PS. 7D12-PS 
showed a peak fluorescence intensity in the tongue 
tumor already at 30 min after administration after 
which it slowly decreased. 7D12-9G8-PS showed a 
high fluorescence intensity in the tumor up to 4 h after 
administration after which it started to decrease. The 
tumor to normal ratio at 1 h after administration was 
1.8±0.3 and 3.8±0.5, respectively. Although the tumor 
to normal ratio increased to 16.1±4.5 and 30.8±0.9, 
respectively at 24 h after administration, the tumor 
fluorescence intensity was significantly lower. 
Therefore, in that study, light was applied 1 h after 
administration for both NB-PS. Histological 
examination 24 h after PDT showed extensive tumor 
necrosis and damage to the vasculature in and close to 
the tumor [16]. 
These promising results encouraged us to 
further investigate, in the present study, the 
distribution of the NB-PS conjugates and 
PDT-induced response in vivo within tumor and 
normal tissue. The (sub-) cellular localization of 
photosensitizer is considered to be important as it 
determines the initial site of photodamage due to the 
short diffusion distance of singlet oxygen [27]. 
Antitumor effects induced by PDT are known to be 
mediated not only by cellular damage but also by 
vascular responses [1]. Interestingly, PDT, and more 
recently targeted PDT, have been shown to be capable 
of increasing the enhanced permeability and retention 
(EPR) effect by improving tumor vessel permeability 
[28-31]. Since this could potentiate the delivery of 
other nanomedicines to the tumor site in future 
combined therapies, in this study we also carefully 
investigate the vascular effects of NB targeted PDT. 
Intravital imaging in a skin-fold chamber model 
can be used to provide longitudinal information on 
the kinetics and localization of fluorophores in detail 
in a living animal, and be used to investigate direct 
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effects on the vasculature [8,32-39]. Therefore, in the 
present study, we used intravital imaging in the 
mouse skin-fold chamber model transplanted with 
the OSC-19-luc2-cGFP tumor, a tumor model we have 
previously investigated in the mouse tongue [16]. We 
investigated the biodistribution of the conjugates and 
the vascular responses induced by NB-PS mediated 
PDT; constriction and leakage, as well as the 
induction of necrosis after illumination at 1 or 24 h 
post administration [16,40-43]. To complement 
intravital microscopy, contrast-enhanced MRI and 
dynamic contrast enhanced (DCE) MRI were also 
used, as these have shown to be effective tools to 
determine the vascular effects and measure the 
microvascular status of tumors early after PDT 
[43-50]. We employed the same tumor cell line but 
now grown subcutaneously in mice for DCE-MRI, to 
interrogate the microvascular status of the tumor and 
underlying muscle [50]. Here, the degree of blood 
perfusion and vessel integrity can be quantified by 
measuring the tissue influx and wash out of a small 
gadolinium-based contrast agent. Histological 
examination of tissues collected directly after or up to 
48 h after PDT was also used to determine the tumor 
necrotic fraction, vascular perfusion and damage to 
endothelial and normal tissue in both models. 
Materials and Methods 
Study design 
Intravital microscopy and DCE-MRI were used 
to investigate the distribution and the direct effects of 
two EGFR-targeted NB-PS conjugates. 
Intravital microscopy combined with the 
skin-fold chamber tumor model was used to study 
fluorescence distribution and PDT response 
longitudinally. Mice wearing the skin-fold chamber 
were divided over 6 groups (Table 1). Fluorescence 
distribution was investigated intravitally in groups 
1-3 by imaging at 1, 2 and 24 h after administration of 
the NB-PS and before PDT. After the last time-point 
(24 h) PDT was performed in an attempt to use the 
high tumor to normal ratio (TNR) observed 
previously [16]. In groups 4-6 PDT was performed 1 h 
after administration. Groups 3 and 6 were light only 
controls. PDT responses were investigated intravitally 
in all groups by imaging directly, 2, 24 and 48 h after 
PDT. At 2 h post illumination tetramethylrhodamine 
dextran was administered and imaged in all groups to 
investigate vascular leakage and flow. At 24 h post 
illumination the necrosis marker HQ4 [41,42] was 
administered and imaged 24 h later. Tissue was 
harvested for ex vivo necrosis marker imaging and 
histological analysis. 
DCE-MR imaging of the solid tumor model was 
used to investigate the PDT response in 2 groups. One 
group of animals (n=5) was injected with 7D12-PS and 
the control group (n=4) received saline. For practical 
reasons only one of the two NB conjugates could be 
investigated and 7D12-PS was chosen. To compensate 
for the prolonged gas-anesthesia necessary for the 
procedure, illumination was performed at 2 h instead 
of 1 h after administration. MR imaging was 
performed on 3 consecutive days, 1 day before 
illumination, approximately 1 h after illumination 
inside the bore of the scanner on the second day and 1 
day after illumination, after which animals were 
sacrificed. Histological analysis was performed on a 
selection of 2 control animals and 3 7D12-PS mediated 
PDT treated animals, which received a perfusion 
marker (Hoechst 33342) 5 min prior to sacrifice. 
 
Table 1. Overview of nanobody-photosensitizer treatment 
schemes studied intravitally for distribution and tumor and normal 
tissue damage. 
Group n Nanobody-PS 
conjugate 
Illumination at HQ4 
 
Harvest 
after ill  
1 8 *, ** 7D12-PS 24 h Yes 48 h 
2 8 *, ** 7D12-9G8-PS 24 h Yes 48 h 
3 3 Saline 24 h Yes 48 h 
4 8 *, ** 7D12-PS 1 h Yes 48 h 
5 8 *, ** 7D12-9G8-PS 1 h Yes 48 h 
6 3 Saline 1 h No 48 h 
* 1 animal without tumor, serving as normal tissue control. 
** 1 animal sacrificed before PDT for fluorescence distribution. 
 
 
Nanobody conjugates 
The nanobody-photosensitizer conjugates 
(NB-PS) 7D12-PS and 7D12-9G8-PS were prepared as 
described previously [15,16]. His-tagged nanobodies 
were produced in E.coli BL21 and purified from the 
periplasmic fraction using Nickel-NTA agarose 
[23,51]. The monovalent nanobody 7D12 binds to 
domain III of the EGFR, preventing EGF-binding to 
the receptor [52]. The biparatopic nanobody 7D12-9G8 
was composed of two nanobodies that bind to 
different epitopes on domain III and due to the short 
linker sequence they cannot bind simultaneously to 
the same receptor, therefore being able to create 
clusters of receptors [52]. Conjugation of 
photosensitizer to the nanobodies was performed as 
described in Heukers et al. 2014 [15], except that the 
molar ratios for conjugation was 1 to 4 for 7D12 and 1 
to 3 for 7D12-9G8. In short, the nanobodies were 
incubated with the photosensitizer IRDye700DX 
(LI-COR Biosciences, Lincoln, Nebraska) for 2 h at 
room temperature. Afterwards, the NB-PS conjugates 
were separated from the free photosensitizer using 
three consequent Zeba spin desalting columns 
(Thermo Fisher Scientific, Perbio Science Nederland). 
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The degree of the conjugation was determined using a 
Nanodrop spectrophotometer as recommended by 
the provider by measuring the absorbance at 280 nm 
and 689 nm. The purity of the NB-PS conjugates was 
determined on 15% SDS-PAGE and imaged on an 
Odyssey infrared scanner (LI-COR Biosciences) using 
700 nm. Afterwards, PageBlue staining was 
performed to show the total protein content. The 
concentration of NB-PS administered was corrected 
for the degree of conjugation, so that every mouse 
received the same amount of photosensitizer, i.e. 6 
nmol IRdye700DX). 
Cell line 
The oral squamous cell carcinoma line, 
OSC-19-luc2-cGFP, was cultured in Dulbecco’s 
Modified Eagle’s Medium (containing 4.5 g 
D-Glucose/L, 110 mg Sodium Pyruvate/L) plus 
GlutaMAXTM, supplemented with 10% Fetal Bovine 
Serum, 1x Minimal Essential Medium non-essential 
amino acids solution and 1x Minimal Essential 
Medium vitamin solution as before [53]. 
Intravital microscopy 
Skin-fold chamber model 
The mouse skin-fold chamber was prepared on 
the back of female Balb/c nu or BalB/cAnNRj mice 
and transplanted with the oral squamous cell 
carcinoma (OSC-19-luc2-cGFP) using a procedure 
adapted from previous studies [54-56]. In brief, mice 
received analgesia 1 h (1 mg/kg rimadyl cattle s.c; 
Pfizer, Capelle a/d IJssel, NL) and anesthesia (75 
mg/kg ketamine i.p.; Alfasan, Woerden, NL and 1 
mg/kg medetomidine i.p.; Eurovet, Bladel, NL) 20 
min before the procedure. The dorsal skin was folded 
and fixed between two frames after removal of one 
side of the skin in 1 cm diameter up to the fascia of the 
opposed skin. A tumor cell suspension of 5x104 cells 
in 10 µL was injected superficially in the 
fascia/subcutaneous musculature and the window 
was closed with a sterile microscope cover glass of 12 
mm diameter secured with a retaining ring. Glass 
spacers (thick cover glasses of 9 mm diameter) were 
placed on the epidermal side of the skin and another 
12 mm circular microscopic cover glass was used to 
close the window on that side. Mice were housed 
individually in climate-controlled cabinets with an 
ambient temperature of 30 °C and a humidity of 70%. 
Experiments started 6-9 days after preparation of 
the chambers. Mice were awake during all i.v. 
administrations. From two weeks prior to the 
experiments, all mice were fed a chlorophyll free diet 
(catalogue number 4208.00, Hope Farms b.v., 
Woerden, NL or #100208, Altromin, Germany) to 
minimize the contribution of pheophorbides to the 
autofluorescence emission spectrum. The animal 
ethics committee of the Erasmus MC approved the 
experimental protocols of the study. 
Fluorescence distribution 
The microscopic distribution of 7D12-PS and 
7D12-9G8-PS was intravitally imaged under gas 
anesthesia at 1, 2 and 24 h after i.v. administration. 
Mice injected with physiological saline served as a 
control. A Zeiss Laser Scanner Confocal Microscope 
510 equipped with 2x, 10x and 20x air Plan-Neofluar 
objectives, a heated stage and a gas anesthesia supply 
unit was used. Fluorescence images were recorded 
with the 2.5x (whole chamber), 10x (1 or 2 tumor areas 
of maximal 7.6 mm2 and 1 normal tissue area) and 20x 
objectives (3 z-stacks of 7 slices, 2 in tumor and 1 in 
normal tissue) using 633 nm excitation and long pass 
650 nm detection for the nanobody-conjugates and 
488 nm excitation and 505-530 nm band pass detection 
for the GFP signal of the tumor. Corresponding 
transmission images were recorded for orientation 
purposes using 488 nm light. Fluorescence and 
transmission images were recorded before, 1, 2 and 24 
h after i.v. administration of the nanobody-conjugates 
under 2-3% isoflurane in oxygen anesthesia. 
Reference standards were recorded every day to 
correct for differences between experiments. Images 
were analyzed using ImageJ-Fiji. Regions of interest 
(ROI) were drawn around tumor and normal tissue 
areas excluding the large venules and arteries based 
on the transmission and GFP images. The ROI’s for 
normal tissue were drawn in regions without any GFP 
signal and distant from larger blood vessels. 
Integrated density was determined and normalized to 
an area of 5000 µm2 rather than the mean fluorescence 
intensity of the pixels since the fluorescence was 
expected to be heterogeneous due to the receptor 
specific binding of the nanobody conjugates and the 
spatial resolution of the images. The integrated 
density was corrected for the dark current, variation 
in the reference standard and the individual 
autofluorescence. For each animal, time point and 
tissue type, 2-6 regions of interest’s were drawn and 
averaged. Colocalization analysis between the GFP 
and red fluorescence signals was performed after 
correction for the dark current, using the Coloc2 
plugin. 
In parallel, for ex vivo microscopy, skin-fold 
chamber tissue of 4 mice was dissected at 1 or 24 h 
after administration of 7D12-PS or 7D12-9G8-PS 
(group 1, 2, 4 and 5). Tissue was snap-frozen and 
stored at -80 °C. Cryosections were made and stained 
with anti-CD31 Brilliant Violet (AntibodyChain BV, 
The Netherlands) for fluorescence microscopy. 
Images were collected using a Leica SP5 Microscope 
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equipped with 40x oil Plan-Neofluar objective, 633 nm 
excitation and 650-800 nm HyD detection for the 
NB-conjugates and 405 nm excitation and 420-450 nm 
detection for the Brilliant Violet signal. Reference 
standards were recorded to correct for differences 
between experiments. 
PDT 
Illumination was performed under gas 
anesthesia on the microscope stage 1 or 24 h after i.v. 
administration of 7D12-PS or 7D12-9G8-PS. A 690 nm 
laser (ML7700, Modulight, Inc. Tampere, Finland) and 
a frontal light distributor (Medlight SA, Ecublens, 
Switzerland) was used to deliver a dose of 100 J.cm-2 
at an irradiance of 50 mW.cm-2. Mice injected with 
physiological saline served as a light only control. 
Cellular response to PDT 
The GFP signal of the tumor cells was used to 
observe changes in the morphology in time after PDT. 
Necrosis was detected intravitally using the necrosis 
avid agent HQ4 (20 nMol/mouse [41,42]) i.v. 
administered 24 h post PDT and imaged 24 h later 
using 633 nm excitation and 650 nm long pass 
detection. Tissue was dissected for ex vivo necrosis 
avid agent imaging and histological analysis. The 
skin-fold chamber tissue was cut in two halves 
through the tumor, snap-frozen in liquid nitrogen and 
stored in -80 °C until sectioning. Sections were 
collected at three depths with alternating thickness of 
50 and 8 µm for HQ4 fluorescence imaging and 
histology respectively and stored in -80 °C until 
imaging. The 50 µm sections were defrosted, dried 
and imaged unfixed and uncovered using a Zeiss 
laser scanner confocal microscope. Fluorescence 
images were recorded with the 10x objective using 633 
nm excitation and long pass 650 nm detection for HQ4 
fluorescence and 488 nm excitation and 505-530 nm 
band pass detection for the GFP signal of the tumor. 
Corresponding transmission images were recorded 
for orientation purposes using 488 nm. Images were 
analyzed using ImageJ-Fiji. Regions of interest were 
drawn around tumor and normal tissue areas. The 
ROI’s selection of tumor were created by thresholding 
the GFP signal and creating a mask of it to ensure that 
only tumor tissue was measured. The fluorescence 
intensity was corrected for the dark current and 
variation in the reference standard for the different 
recording days. 
Thereafter tissues were formalin fixed and 
paraffin embedded (FFPE) for histological 
examination. The FFPE tissues were sectioned and 
stained with hematoxylin and eosin (H&E) and 
analyzed as described by van Driel et al. [16]. 
Vascular response to PDT 
The vascular responses to PDT were investigated 
using both transmission imaging and tetramethyl-
rhodamine dextran imaging. Tetramethylrhodamine 
dextran (2000 kDa, 1 mg/ml, 0.1 mg mouse, D7139, 
Thermo Fisher Scientific, Molecular Probes, Eugene, 
Oregon, USA) was administered 2 h post PDT and 
imaged intravitally within 20 min using 543 nm 
excitation and 560-615 nm bandpass detection and the 
20x objective. The number of animals showing 
leakage in tumor or normal tissue, i.e., 
tetramethylrhodamine fluorescence outside the 
vessels, was counted. Tumor vascular flow was 
scored based on the appearance of the 
tetramethylrhodamine fluorescence according to 
three criteria, i.e., lack of flow (no fluorescence in the 
vessels), reduced flow (disrupted fluorescence in the 
vessels) or normal flow (fluorescence confined to the 
vessels). The proportional area of tumor tissue that 
was affected by each criterion was estimated. 
Transmission images using 488 nm were recorded 
immediately, 2, 24 and 48 h after PDT using the 2.5x 
objective to investigate changes in vascular 
architecture. The severity of the changes in vascular 
architecture in normal tissue was scored as follows: 
No change in vascular lumen and flow visible (-), 
minimal changes in vascular lumen of the larger 
vessels and/or capillary shutdown (+), severe 
changes in vascular lumen and flow visible in areas 
(++) and severe changes in vascular lumen and no 
flow visible (+++). 
DCE-MRI 
Solid tumor model 
Female BALB/c nude mice (Charles River) aged 
8-11 weeks were subcutaneously injected with 1x106 
cells in the right hind limb. Tumors became palpable 
after 3 to 6 days and were measured with a caliper 
every 2 or 3 days. MRI experiments were started 
when the tumors reached a volume of approximately 
300 mm3. The Animal Care and Use Committee of 
Maastricht University approved the protocol. All 
applicable institutional and/or national guidelines for 
the care and use of animals were followed. 
PDT 
Mice were anesthetized during injection of 
7D12-PS or physiological saline until PDT and MRI 
imaging using 2-3% isoflurane in oxygen anesthesia. 
Body temperature was monitored with a rectal probe 
and maintained at 37 °C using a warm water circuit. 
Respiration rate was monitored using a pressure 
balloon. PDT was performed 2 h after administration 
and not 1 h to compensate for the lower metabolism 
caused by the prolonged gas anesthesia needed for 
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the procedures. Light was delivered using a 690 nm 
laser (ML7700, Modulight, Inc. Tampere, Finland) via 
a fiber and collimating lens into the MR magnet to a 
dose of 100 J.cm-2 at an irradiance of 50 mW.cm-2. A 
black paper mask was placed surrounding the tumor 
to protect the rest of the animal from stray light. 
MRI 
Experiments were performed using a 7T MRI 
scanner (BioSpec 30/70 USR, Bruker, Billerica, 
Massachusetts, USA) with a 72 mm diameter 
quadrature transmit and receive birdcage coil. Briefly, 
T2-weighted anatomical reference scans were 
acquired followed by a 3D pre-contrast T1 map. Then, 
a 15 min 3D DCE-MRI scan was performed with a 
temporal resolution of 3.5 s, to capture the dynamic 
influx of contrast agent (Dotarem) in the tissue. Based 
on the DCE-MRI data, all pixels were classified as 
enhanced or non-enhanced, and the following 
variables were calculated for each pixel: the area 
under the curve (AUC) of the Dotarem concentration, 
and Ktrans (transfer constant describing contrast 
exchange between blood plasma and the 
extravascular extracellular space). For anatomical 
reference a T2 weighted multi-slice spin echo scan was 
acquired with 12 to 14 axial slices, covering the entire 
tumor. Scan parameters were: TR=1000ms, TE=30 ms, 
matrix=128x128, slice thickness=1.0 mm, slice gap=0.1 
mm, FOV=4x4 cm2. For T1-mapping, a 3D FLASH 
sequence with variable flip angle was used [57]. 
Sequence parameters were: TR-20 ms, TE=3.2 ms, 7 
flip angles (2º, 3º, 5º, 7º, 10º, 13º and 20º), matrix=128x 
128x39, FOV=40x40x22 mm3. DCE-MRI was 
performed using the same 3D FLASH sequence with 
shorter TE and TR and a fixed flip angle (1 ms, 3 ms 
and 7º respectively) and an acquisition matrix of 
128x128x17 (zero-filled to 128x128x39). Two min after 
the start of the scan, a dose of 0.3 mmol/kg b.w. 
Dotarem (Guerbet, Villepinte, France) was injected in 
5 s using a syringe pump (Fusion 100, Chemyx Inc., 
Stafford, 153 TX, USA), followed by a saline flush. 
Manual segmentation of tumors was performed 
in ITK-SNAP [58], based on T2-weighted spin echo 
images. Tumor was hyper intense compared to 
muscle tissue. All further analysis was performed 
using home-made scripts in Matlab 2016a 
(Mathworks, Natick, MA). Muscle ROI’s of 5x5 pixels 
were selected in four central tumor slices, with 1 pixel 
spacing to the tumor border and centered on the 
optical axis of the light beam. T1 maps were 
reconstructed pixel by pixel by fitting the data signal 
intensities at different FA to the spoil gradient echo 
sequence equation: 𝑠𝑠 = ∝ 𝑠𝑠in(𝐹𝐹𝐹𝐹) (1 − exp �− 𝑇𝑇𝑇𝑇
𝑇𝑇1
�)/(1 − cos(𝐹𝐹𝐹𝐹) exp �− 𝑇𝑇𝑇𝑇
𝑇𝑇1
�). Dynamic changes in R1(t) = 
1/T1(t) were calculated from the DCE-MRI scan, based 
on the pre-contrast relaxation rate R1,pre = 1/T1,pre and 
the signal during contrast agent influx, using the same 
equation. Next, Dotarem concentration curves C(t) 
were calculated using R1(t)=R1,pre + r1C(t), where r1 = 
3.53 s-1mM-1 is the longitudinal relaxivity of Dotarem 
[59]. Pixels were classified as non-enhanced when the 
median of the concentration curve after time of 
contrast injection was smaller than twice the SD 
before injection. Tracer kinetic modelling was 
performed using the standard Tofts-Kermode model 
[60], to estimate Ktrans and ve (the volume fraction of 
the extravascular extracellular space). The arterial 
input function was defined as a bi-exponential 
function with amplitudes A1 = 5.36 mM and A2 = 1.27 
mM, and time constants 𝜏𝜏1 =5.36 s and 𝜏𝜏2 = 915 s, as 
previously described [49]. 
Histological analysis 
The subcutaneous solid tumor tissue samples 
were collected 5 min after administration of Hoechst 
33342 (i.v., 32 mg/kg b.w. B2261, Sigma Aldrich, St. 
Louis, MO, USA), snap-frozen in liquid nitrogen and 
stored in -80 °C until sectioning and analysis. A series 
of sections were collected from a central and 
peripheral transverse plane and subjected to either 
hematoxylin and eosin staining (H&E) or CD31 
immunofluorescence staining to detect endothelial 
cells. For CD31 detection, sections were fixed in 
acetone (5 min RT), air dried, incubated with 
biotin-conjugated rat anti-mouse CD31 antibodies (1 h 
1:250 RT, #102503, Biolegend, San Diego, CA, USA) 
and DyLight 649-conjugated streptavidin (1 h 1:100 
RT, #405224, Biolegend). Bright field and fluorescence 
imaging were performed by mosaic acquisition at 40x 
and 20x respectively. Viable and necrotic regions in 
H&E were manually segmented in ImageJ 1.51. All 
other data analysis, including segmentation of tumors 
in CD31 images were performed using home-made 
scripts in Matlab 2016a. In the CD31 images, tissue 
was classified as perfused or non-perfused by 
applying a manually selected threshold on the 
fluorescence signal intensity of Hoechst 33342. 
Statistics 
Results of the fluorescence intensity of NB-PS or 
necrosis marker are presented as weighted mean ± 
SD, weighted by the SD of the mean fluorescence 
intensity of 2-6 ROI’s at a certain time point for a 
certain tissue type. For each tissue type and time point 
the individual fluorescence intensity at a certain time 
point was weighted by its SD to result in a weighted 
mean calculated by averaging the different ROIs and 
weighted by the SD of that mean. The significance of 
differences was determined using the student 
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t-test/ANOVA/SNK and p<0.05 was considered 
significant. The Spearman’s rank correlation 
coefficient of the colocalization of the photosensitizer 
with the GFP fluorescence is presented as mean ± 
SEM and statistically analyzed using the student t-test 
and p<0.05 was considered significant. 
Results 
Fluorescence distribution of NB-PS conjugates 
Intravital microscopy imaging was performed to 
determine potential differences in the distribution 
between the two EGFR-targeted NB-PS in tumor and 
in normal tissue immediately surrounding the tumor 
(Figure 1A). With respect to the intensity, both 
conjugates showed more fluorescence in tumor than 
in distant normal tissue, at either 1 or 2 h after 
administration with p=0.04 and 0.03 for 7D12-PS, and 
p=0.04 and 0.06 for 7D12-9G8-PS, respectively (Figure 
1B). The tumor to normal tissue ratio for the two 
conjugates was significantly higher for 7D12-9G8-PS 
(p<0.01) but only at 2 h after administration. The 
tumor to normal tissue ratio at 1 and 2 h after 
administration was 3.0±0.7 and 2.6±0.4 for 7D12-PS, 
and 2.9±0.6 and 4.0±0.2 for 7D12-9G8-PS, respectively. 
Comparing the two conjugates, more fluorescence 
was observed in tumor and normal tissue after 
7D12-9G8-PS administration at all time points.  
Distinct differences could be observed in the 
sub-cellular distribution of the two NB-PS conjugates 
using z-stack imaging with a higher magnification 
(Figure 2A). 7D12-9G8-PS showed an intense, 
membrane localized, fluorescence pattern in tumor 
cells. This was different after 7D12-PS administration, 
for which the fluorescence in the tumor tissue was 
more diffuse. In one animal we were able to image the 
internalization of 7D12-9G8-PS (Figure 2B). At 1 h 
after administration the fluorescence was visible at 
the membrane, and at 2 h fluorescence was clearly 
visible in the interior of the cell. 
 
 
Figure 1. (A) Example of intravital fluorescence images recorded of the tumor in the skin-fold chamber 1 h after administration of 7D12-PS or 7D12-9G8-PS. Bar is 200 µm. 
White arrows highlight fluorescence close to vessels that surround tumor tissue. (B) Fluorescence intensity in tumor (solid squares and lines) and normal tissue far from tumor 
and not showing GFP signal (open squares and dashed lines) in the skin-fold chamber after administration of physiological saline, 7D12-PS or 7D12-9G8-PS. Weighted mean ± SD, 
n=3, 6, 8 respectively. Significant differences between tumor and normal tissue with p<0.05 (*). 
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Figure 2. (A) Example of high magnification fluorescence images recorded 1 h after administration of 7D12-PS and 7D12-9G8-PS. Bar is 50 µm. (B) Consecutive images recorded 
in one animal at 1 and 2 h after administration of 7D12-9G8-PS fluorescence (red) in tumor (green) cells. Bar is 20 µm. (C) The Spearman’s rank correlation coefficient for GFP 
fluorescence of tumor (green) and NIR fluorescence (red) of 7D12-PS (white bars) and 7D12-9G8-PS (black bars). Mean ± SEM and n=6 and 7 respectively. Significantly difference 
between time before and after administration with p<0.01 (*), p<2x10-4 (#) or p<2x10-6 (+). Significant difference between 7D12-PS and 7D12-9G8-PS with p<0.003 (§). 
 
Colocalization analysis between the NB-PS 
fluorescence and the GFP signal in the tumor showed 
significant higher Spearman’s rank correlation 
coefficients for 7D12-PS at 1 and 2 h after 
administration, compared to before administration, 
suggesting tumor specific binding with p<0.01 for 
both time points (Figure 2C). For 7D12-9G8-PS, all 
time points after administration showed significant 
higher Spearman’s rank coefficients compared to 
before administration with p<2x10-6 for 1 and 2 h, and 
p<2x10-4 for 24 h after administration. Overall, 7D12- 
9G8-PS showed a significantly higher correlation 
between NB-PS fluorescence and GFP signal 
compared to 7D12-PS at all time points with p<0.003. 
Normal tissue showed a heterogeneous 
fluorescence pattern. For both conjugates, 
fluorescence was present in close proximity of 
vasculature in chambers, with and without tumor 
(white arrows in Figure 1A). Line profiles obtained 
perpendicularly over larger vessels showed up to a 4x 
higher fluorescence intensity close to the vessels 
compared to further from the vessel (data not shown). 
In order to determine the localization of the 
fluorescence more carefully, tissue was harvested at 1 
or 24 h after administration of the NB-PS, sectioned 
and stained for endothelial cells (CD31 fluorescent 
detection). Ex vivo fluorescence microscopy showed 
high fluorescence intensities for both NB-PS in normal 
tissue associated with the endothelial cells of (larger) 
blood vessels (Figure 3). 
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Figure 3. Example of PS fluorescence in the subcutaneous musculature and lower 
dermis of the skin-fold chamber tissue after administration of (A) saline, 7D12-PS at 
(B) 1 h or (C) 24 h after administration, or 7D12-9G8-PS at (D) 1 h or (E) 24 h after 
administration. Photosensitizer fluorescence is depicted in red, CD31 in blue and 
colocalization is shown in magenta. Bar is 50 µm. 
 
Responses to nanobody targeted PDT 
Since the acute response to PDT is a complex 
mixture of cellular and vascular responses, we 
investigated both using different techniques. Initial 
tumor cell responses were assessed by observing 
changes in the GFP signal using intravital imaging. 
Vascular responses were investigated with intravital 
fluorescence imaging for vascular flow and leakage 
(tetramethylrhodamine dextran), intravital 
transmission imaging for vascular architecture; and 
DCE-MRI for assessment of vascular perfusion. These 
were combined with ex vivo histology for evaluation 
of necrosis marker (HQ4) and of (permanent) tissue 
necrosis. 
Tumor cellular responses 
Distinct changes to the morphology of tumor 
cells were observed in the GFP fluorescence images 
recorded in time, after illumination at 1 h (Figure 4). 
Before illumination, the GFP signal was confined to 
the tumor cells, with high fluorescence intensity in the 
cytoplasm compared to the nucleus. In light only 
controls, the number of GFP containing cells increased 
in the 24 h after illumination, thus reflecting tumor 
growth. In NB-PS treated animals that were 
illuminated 1 h after administration, the normal 
cellular GFP fluorescence pattern, in some cases, 
changed significantly. In those cases the GFP 
fluorescence appeared more diffuse and/or confined 
to circular spots of different diameters with high 
fluorescence intensities, suggesting tumor cell 
damage. This was seen in more animals treated with 
7D12-9G8-PS than with 7D12-PS (10/13 fields vs 3/12 
fields, respectively) and was not observed for PDT 
treatments 24 h after administration (data not shown). 
Fluorescence imaging of cryosections of the tissues 
collected 48 h after PDT showed similar results 
(Figure 4). 
Vascular responses 
Vascular leakage of tumor and normal tissue 
vessels was observed for both NB-PS treated groups. 
But there was no clear relationship between the 
number of tumors that showed leakage and the 
conjugate used or the time at which the light was 
delivered (Table 2). The proportional area of tumor 
that showed either lack of flow or reduced flow 2 h 
post PDT was similar for both conjugates when light 
was applied 1 h after administration (Figure 5). The 
severity of the vascular response decreased 
significantly when the light was delivered at 24 h after 
administration, as the size of the area with lack of flow 
decreased from 51% to 8% with p=0.029 for 7D12-PS 
and from 55% to 10% with p=0.033 for 7D12-9G8-PS. 
Comparing the two conjugates, a larger area of tumor 
showed reduced flow 2 h post illumination at 24 h 
after administration of 7D12-PS compared to 
7D12-9G8-PS (Figure 5). 
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Figure 4. Examples of the effect of PDT on the morphology of tumor cells intravitally imaged in the skin-fold chamber, at 1 h post administration of saline (top), 7D12-PS (middle) 
and 7D12-9G8-PS (bottom) up to 24 h after PDT. Arrows point to the same cell cluster in every image for each group. The last column displays the GFP fluorescence images of 
cryosections obtained 48 h after PDT. Bar 50 µm. 
 
 
Figure 5. Representative images showing the different tumor vascular responses 
observed 2 h after PDT recorded using GFP fluorescence (green) and 
tertramethylrhodamine dextran fluorescence (yellow). Bar is 100 µm. (A) Normal 
blood flow in the tumor and leakage (L) just outside the tumor. (B) Tumor with an 
area of no flow (I), reduced flow (II) and normal flow with leakage (III). (C) 
Qualitative analysis of vascular flow in tumor determined 2 h after PDT using 
7D12-PS or 7D12-9G8-PS and illuminated either at 1 or 24 h post administration. 
The relative area in tumor that showed either no flow (black), reduced flow (gray) 
or normal flow (white) was determined and averaged in 6 animals. 
 
DCE-MRI imaging of the solid tumors after 
7D12-PS mediated PDT showed tumor non- 
enhancement values that were in agreement with 
the proportion of tumor showing lack of flow in the 
skin-fold chambers (Figure 6A-B). Directly after and 
24 h after 7D12-PS mediated PDT, 42.8±22.6% and 
61.9±21.4% of the tumor showed non-enhancement, 
i.e., loss of contrast agent uptake, which was 
significantly increased compared to baseline 
(p=0.01 and 4.6810-4, respectively). In agreement 
with the loss of contrast agent, uptake in tumors 
showed negligible Ktrans values throughout the 
whole tumor at both time points (Figure 6C-D). The 
remaining pixels with residual contrast 
enhancement mostly showed lower Ktrans values 
compared to untreated tumor tissue. Most parts of 
the underlying muscle showed a decrease in Ktrans 
immediately and 24 h after PDT, suggesting 
impaired microvascular perfusion, although this 
was not statistically significant (p=0.13 and 0.24 
respectively). 
The normal skin vasculature showed 
constriction of the larger arterioles and venules, and 
also changed vascular architecture post NB-PS 
mediated PDT. Comparing the two conjugates, 
slight differences were observed, 1 animal showed 
more severe constriction 2 h post PDT using 
7D12-PS compared to 7D12-9G8-PS but this was 
reversed 48 h after PDT. Illumination at 24 h after 
administration resulted in slightly more vascular 
constriction at 24 and 48 h post PDT for 7D12-PS 
compared to 7D12-9G8-PS. Overall, these effects 
were not significantly different for the two 
conjugates, only more severe for illumination at 1 h 
compared to 24 h after administration (Figure 7). 
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Figure 6. (A) Representative AUC maps of a control and 7D12-PS mediated PDT treated animals recorded at baseline, post PDT and 24 h post PDT. The red contours outline 
the tumor, the red squares represent muscle ROI. (B) Group averages of the non-enhanced fraction pre PDT (black), post PDT (grey) and 24 h post PDT (white) in enhanced 
tumor and muscle ROI’s. Significant differences from pre PDT in same group are indicated with p=0.05 (*) or p=0.005 (**). (C) Representative Ktrans maps of a control and 
7D12-PS mediated PDT treated animal recorded at baseline, post PDT and 24 h post PDT. The red contours outline the tumor, the red squares represent muscle ROI. (D) 
Group averages of the mean Ktrans pre PDT (black), post PDT (gray) and 24 h post PDT (white) in enhanced tumor pixels and muscle ROI’s. Significant differences from pre PDT 
from same group or between groups are indicated with p=0.05 (*) or p=0.005 (**). 
 
Figure 7. (A) Representative images of the changes in vascular architecture in the skin-fold chamber tissue collected longitudinally before and in time after NB-PS mediated PDT 
delivered 1h post administration. Bar = 1000 µm. (B) Severity of the change in vascular architecture in normal tissue per mouse scored at different time points after PDT at 1 or 
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24 h using 7D12-PS or 7D12-9G8-PS. No change in vascular lumen and normal blood flow was scored white (-), capillary shutdown and or small changes in vascular lumen (light 
grey, +), severe changes is vascular lumen but blood flow observed (dark grey, ++) and severe changes in vascular lumen and no flow observed (black, +++). 
Table 2. Number of animals showing vascular leakage in tumor 
and normal tissue 2 h post PDT using either 7D12-PS or 
7D12-9G8-PS and illumination at either 1 or 24 h after 
administration.  
Conjugate Tumor  Normal tissue close to tumor 
1 h 24 h 1 h 24 h 
7D12-PS 4/6 2/6 1/3 *2 3/4 *1 
7D12-9G8-PS 3/8 4/6 5/6 3/5 
* number of animals not scored due to lack of flow  
 
 
Figure 8. Fluorescence intensity of the necrosis marker HQ4 in cryosections of the 
skin-fold chamber collected 48 h after PDT at 1 h post administration of physiological 
saline, 7D12-PS, 7D12-9G8-PS, and after PDT at 24 h post administration of 7D12-PS 
and 7D12-9G8-PS ROI’s were drawn around tumor (black bar) and sub cutaneous 
musculature around and away from tumor (fat or thin dashed bar) respectively. 
Weighted mean ± SD, n=1-6 animals per group and 2-3 sections per animal. 
 
Tumor and normal tissue viability and necrosis 
The PDT induced vascular responses and edema 
significantly changed the tissue optical properties of 
tissues in the window chamber, rendering intravital 
imaging of the necrosis avid agent HQ4 48 h after PDT 
impossible. Therefore, imaging of HQ4 was 
performed on cryosections of excised tissues. More 
fluorescence of HQ4 was observed in tumors treated 
with NB targeted PDT compared to the light only 
controls (Figure 8). While it is unknown if there is a 
linear relationship between HQ4 fluorescence 
intensity and necrosis, the data suggests more 
necrosis for illumination at 1 h after administration 
compared to 24 h after administration. 
H&E staining of the skin-fold chamber tissues 
also showed more tumor necrosis for illumination at 1 
h compared to 24 h post administration (Figure 
9A-D). PDT at 1 h after administration induced 88 or 
80% necrosis in tumors compared to 30 or 0% at 24 h 
for 7D12-PS and 7D12-9G8-PS, respectively. 
Complementary to this, a similar average necrotic 
tumor fraction was determined in H&E sections of the 
solid tumor model for treatment with 7D12-PS 
mediated PDT at 2 h (89±9% , compared to 23±20% in 
light only controls). Fluorescence imaging of Hoechst 
33342 in adjacent sections showed co-localization of 
those areas with the non-perfused areas (74±17% and 
23±33%, respectively). Tumors treated with 7D12-PS 
mediated PDT hardly showed any uptake of Hoechst 
33342 and fewer blood vessels were detected. Blood 
vessels had weak staining and indistinct morphology, 
possibly due to disruption and closed lumina (Figure 
9E-H). 
Concerning normal tissues, damage to these in 
the skin-fold chamber model was similar for both 
NB-PS conjugates used (Table 3). PDT delivered 1 h 
after administration resulted in severe damage to the 
normal tissues close to tumor. Away from the tumor, 
the damage was mild. No damage to normal tissues 
was observed when PDT was performed 24 h after 
administration. Also, the skin-fold chambers without 
tumor showed no damage to normal tissues 48 h after 
PDT at either 1 or 24 h post administration (n=1 per 
group). 
 
Table 3. Degree of tissue damage scored in H&E sections of the 
skin-fold chamber collected 48 h after PDT with 2 anti-EGFR 
nanobody-photosensitizer conjugates. Mean of 3 to 5 animals per 
group. 
 Control 7D12-PS 7D12-9G8-PS No tumor 
 1 h 24 h 1 h 24 h All NB-PS  
1 or 24h 
Damage to 
epithelium 
- +++ + +++ - - 
Damage to muscle 
cells 
around tumor  
- +++ - +++/++ - - 
Damage to muscle 
cells 
away from tumor 
- ++ - ++/+ - - 
Damage to blood 
vessels 
around tumor  
- +++ - +++ - - 
Damage to blood 
vessels 
away from tumor 
- ++ - ++/+ - - 
Neutrophils Few Some Some Few Few - 
 
Discussion 
The present study was designed to investigate 
the biodistribution of two NB-PS, the cellular 
responses to and the vascular effects of 
EGFR-targeted PDT in vivo using intravital 
microscopy and DCE-MRI, complemented with ex 
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vivo analysis of necrosis. 
The overall fluorescence kinetics determined 
with intravital microscopy were similar to those we 
have previously reported for the orthotopic mouse 
tongue model using quantitative fluorescence fiber 
optic spectroscopy [16]. In both cases, we have shown 
more NB-PS fluorescence in tumor than in normal 
tissue, and that the mean intensity was higher after 
administration of biparatopic 7D12-9G8-PS, 
compared to monovalent 7D12-PS. Intravital micro-
scopy imaging however, revealed a heterogeneous 
fluorescence pattern in tumor that was different for 
the two conjugates. 7D12-9G8-PS showed a 
membrane bound fluorescence pattern in tumor, 
which was not observed for 7D12-PS. The reduced 
disassociation kinetics of 7D12-9G8-PS compared to 
7D12-PS and/or the induced internalization of 
7D12-9G8-PS might play a role in the observed higher 
fluorescence intensity and the more membrane bound 
fluorescence pattern for 7D12-9G8-PS [15]. Previously, 
the highest fluorescence intensity of 7D12-PS was 
detected in tumor 30 minutes after administration 
with a clear decrease thereafter, whereas for 7D12- 
9G8-PS the fluorescence intensity remained high for at 
least 4 h after administration [16]. 7D12-PS may be 
already dissociating from the receptor at early time 
points after administration and therefore showing less 
membrane localization at 1 and 2 h after 
administration. Internalization of 7D12-9G8-PS has 
been shown in vitro and was observed only once 
intravitally, possibly because of the many factors that 
influence the effective resolution of intravital imaging 
[24]. 
Consistent with the visual observation, 
colocalization analysis between GFP signal and 
photosensitizer fluorescence showed significantly 
higher Spearman’s rank correlation coefficients, 
compared to the background, for both conjugates, 
suggesting tumor specific binding in time after 
administration which was significantly higher for 
7D12-9G8-PS compared to 7D12-PS.While this study 
was focused on targeted PDT, targeted NB-PS 
conjugates have the potential to be used in 
fluorescence image guided surgery [51,61-63]. 
Complete tumor resection relies on the surgeon’s 
ability to differentiate between malignant and benign 
tissue but the infiltrative nature of cancerous tissue 
may hinder this. Fluorescence image guided surgery 
may assist a surgeon in delineating the cancerous 
tissue in the surgical field. NB-PS conjugates with 
their small size, high penetration and targeting 
characteristics, combined with fast clearance when 
unbound, could be excellent candidates for 
fluorescence image guided surgery. Clearance should 
be rapid enough to not have side effects of being 
photosensitive and long enough to last through the 
surgical procedure. Comparing the two conjugates in 
this study, 7D12-9G8-PS seems to be a good 
candidate, because of the high correlation coefficient 
between 7D12-9G8-PS fluorescence and tumor cells 
and the prolonged increased tumor fluorescence 
intensity in time after administration. 
In normal tissue, a similar heterogeneous 
fluorescence distribution was found for both NB-PS, 
each showing fluorescence in the fascia and 
endothelial tissue up to 24 h after administration. We 
 
Figure 9. Example of H&E stained sections of the skin-fold chamber 48 h after PDT at 1 h post administration of (A) physiological saline, (B) 7D12-PS or (C) 7D12-9G8-PS. 
Tumor is outlined with dashed lines. Black bar is 200 µm. (D) Individual percentages of tumor necrosis and the median per treatment. Representative examples of (E,G) H&E 
bright-field images and (F,H) CD31 & Hoechst 33342 fluorescence images of (E,F) control and (G,H) 7D12-PS mediated PDT treated solid tumors. CD31 is displayed in red and 
Hoechst in blue. White bar is 100 µm. 
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have previously detected NB-PS fluorescence in 
normal mouse tissues, such as tongue and skin, using 
fiber optic spectroscopy [16]. But fiber optics 
spectroscopy reveals only information in intensity 
and not on cellular distribution. In the present 
intravital microscopy study, we observe that there are 
inhomogeneously distributed high intensities in the 
fascia and (close to) endothelial cells. Based on our 
current understanding of EGFR-targeted NB-PS, it is 
unclear why conjugates are present in normal tissue 
of the skin-fold chamber. 
PDT induced damage is, in general, the result of 
a complex mixture of direct tumor cell damage, the 
influence of the (tumor) vascular responses and the 
immunological responses to these effects [1]. In the 
previous study, we showed necrosis of the tumor 
combined with loss of CD31 and an increased 
presence of neutrophils after NB-PS mediated PDT 
[16]. Our results here show membrane-localized 
fluorescence in tumor cells and also endothelial 
cell-associated fluorescence in the vasculature, thus 
considering the short diffusion distance of singlet 
oxygen, these are likely the primary sites of 
photodamage [27]. 
To assess the effects of NB-targeted PDT, first the 
morphology of the tumor cells was visualized using 
GFP fluorescence imaging. In some cases, the cellular 
GFP fluorescence pattern showed diffuse fluorescence 
and/or high fluorescence intensities confined to 
circular spots of different diameters, as early as 2 h 
after PDT, suggesting the degradation of tumor cells. 
In agreement with the difference in fluorescence 
intensity, and probably also with the differences in 
localization, more animals treated with 7D12-9G8-PS 
mediated PDT at 1 h post administration showed 
degradation of tumor cells compared to 7D12-PS. 
Based on these results, a difference in PDT-induced 
necrosis between the two conjugates might be 
expected but was not observed to be statistically 
significant. Ex vivo fluorescence imaging of HQ4, a 
necrosis avid cyanine probe [41,42], showed more 
tumor necrosis after 7D12-9G8-PS compared to 
7D12-PS mediated PDT when light was applied 1 h 
after administration. However, while it is unknown if 
there is a linear relationship between HQ4 
fluorescence intensity and necrosis, little can be said 
about the significance of this result. Histological 
evaluation of tumor necrosis showed slightly, but not 
significantly more, necrosis post 7D12-PS compared 
to 7D12-9G8-PS mediated PDT. 
Vascular responses are a known contributor to 
the overall PDT response and those were broadly 
similar for both conjugates. Tumor vascular leakage 
was observed in more than 50% of the treated tumors 
within 2 h after PDT (Table 2). In our previous study 
we showed damage to the vasculature by histological 
evaluation 24 h post PDT [16]. In the present study we 
did not find large differences in the magnitude of 
vascular responses for each conjugate. We did not 
investigate the effects of different NB-PS doses on the 
vasculature and overall response to PDT. It is likely 
that higher or lower doses of NB-PS will lead to 
different vascular responses in tumor and normal 
tissue depending also on the oxygen availability and 
the light applied. 
The vascular effect of PDT could be utilized to 
enhance the EPR effect, in combined therapies with 
nanosized drug delivery systems [29-31]. Employing a 
NB specifically designed to target the tumor 
vasculature could possibly increase this response 
even further. However, this should be investigated 
with caution, as tumor vascular stasis was also 
observed in 51-54% of the tumor areas 2 h after PDT, 
detected with rhodamine dextran fluorescence. This 
decreased perfusion was also confirmed through 
DCE-MRI of the subcutaneous tumor model, 1 h after 
7D12-PS mediated PDT. This illustrates that any 
combination with PDT needs to be carefully 
investigated so that there is an optimal enhancement 
of the EPR effect. Tumor cell targeted, endothelial cell 
targeted, and conventional PDT might affect the 
vasculature differently. Therefore, intravital 
microscopic detailed studies, such as the one we 
present here, are critical to investigate a possible time 
window in which leakage could be exploited, before 
perfusion is compromised. 
In line with the fluorescence localization of the 
conjugates, normal tissue showed significant changes 
in the vascular architecture of skin-fold chambers 
after PDT that were more severe for PDT at 1 h 
compared to 24 h. Histological examination revealed 
abundant damage to the subcutaneous musculature 
and fascia after PDT at 1 h but not at 24 h (Table 3). It 
would be interesting to investigate the vascular effects 
with a slightly longer time between administration 
and illumination, but significantly shorter than 24h, or 
with lower doses of the NB-PS conjugates. Perhaps 
then less vascular damage in normal surrounding 
tissues would be observed, though with the risk of 
decreased tumor damage, which after all is the main 
goal. Skin-fold chambers not transplanted with 
tumors showed similar changes in the vascular 
architecture (detected with intravital microscopy) but 
no damage to the musculature or to blood vessels 
(detected in tissue sections). This suggests that the 
vascular effects in normal tissue are transient when no 
tumor is present, and that, when tumor is present, the 
responding tumor contributes to the damage of 
surrounding normal tissue. 
PDT at 24 h post administration was investigated 
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in an attempt to utilize the higher tumor to normal 
ratio. Increasing the time between administration and 
illumination from 1 h to 24 h resulted in less vascular 
responses in tumor and normal tissue (much smaller 
tumor area showed lack of flow and less changes in 
normal vascular architecture) but also significantly 
less tumor response. At 24 h after administration, 
7D12-9G8-PS still showed significant, although lower, 
colocalization of photosensitizer fluorescence with 
GFP suggesting that tumor cells would respond to 
PDT. However, the GFP fluorescence pattern of tumor 
cells after PDT had not changed, suggesting lack of 
tumor cell degradation. Indeed, histological 
evaluation showed a much lower necrotic tumor 
fraction after PDT at 24 h. In addition, HQ4 
fluorescence also showed decreased necrosis in tumor 
and normal tissue after PDT at 24 h compared to 1 h. 
Although the TNR is much higher at 24 h after 
administration, the fluorescence intensity in the 
tumor was significantly lower. The current data 
clearly show that a high TNR is not the only factor in 
an effective treatment scheme: the concentration of 
NB-PS in the tumor is critically important. This result 
is in agreement with results from our previous study 
in the oral cavity [16]. 
The data presented here confirm that the overall 
acute response to EGFR-targeted NB-PS mediated 
PDT is not just a tumor cell specific response but a 
complex mixture of tumor cell responses and vascular 
effects. From a clinical perspective the combination of 
direct tumor cell death and tumor vascular damage is 
likely to be necessary for a maximally effective 
treatment. 
In summary, we have obtained insights with 
unprecedented detail for targeted PDT, which are 
significant at present, since EGFR-targeted PDT using 
antibodies as carriers is currently being tested in 
phase I/II clinical trials [64]. NB-PS conjugates 
7D12-PS and 7D12-9G8-PS targeting EGFR showed 
significant tumor localization in vivo, which was 
higher for 7D12-9G8-PS. The significant higher tumor 
colocalization combined with the prolonged 
fluorescence intensity in time after administration 
makes 7D12-9G8-PS a good candidate for fluorescence 
image guided surgery. Illumination at 1 h after 
administration of either conjugates leads to significant 
tumor necrosis. Despite the difference in fluorescence 
intensity, no significant difference was observed in 
the overall acute tissue response; both EGFR-targeted 
NB-PS mediated PDT treatments lead to similar 
amount of tumor necrosis 2 days post treatment and 
no large differences in vascular responses. Growth 
delay studies are now needed to show the long-term 
efficacy of nanobody-targeted PDT. 
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